Rate of cyp51A mutation in Aspergillus fumigatus among lung transplant recipients with targeted prophylaxis
Open Access
- 20 January 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 70 (4) , 1064-1067
Abstract
The most common mechanism of azole (itraconazole and voriconazole) resistance in Aspergillus fumigatus is a mutation at the cyp51A locus. The aim of our study was to determine the rate of cyp51A mutations in lung transplant recipients (LTR) undergoing targeted antifungal prophylaxis with 12 weeks of voriconazole. We conducted a prospective study that included 22 LTR with A. fumigatus between October 2008 and November 2011. Of those, 10 LTR were colonized with A. fumigatus and 12 had invasive pulmonary aspergillosis. Four patients were found to have A. fumigatus isolates with a cyp51A mutation, two had colonization and two had invasive pulmonary aspergillosis. The remaining 18 LTR had WT cyp51A A. fumigatus isolates. All A. fumigatus isolates (except one due to mixed growth) were tested for antifungal susceptibility. A total of nine LTR were exposed to azoles prior to A. fumigatus isolation for a median duration of 249 (IQR 99–524) days. Azole exposure preceded the isolation of two mutant isolates and seven WT isolates. None of the cyp51A mutant isolates conferred phenotypic resistance to azoles. Targeted antifungal prophylaxis in LTR did not lead to cyp51A resistance mutations in this cohort. Data on larger cohorts who receive universal antifungal prophylaxis are needed.Keywords
This publication has 19 references indexed in Scilit:
- Composite Survival Index to Compare Virulence Changes in Azole-Resistant Aspergillus fumigatus Clinical IsolatesPLOS ONE, 2013
- Azole Preexposure Affects the Aspergillus fumigatus Population in PatientsAntimicrobial Agents and Chemotherapy, 2012
- Rapid Induction of Multiple Resistance Mechanisms in Aspergillus fumigatus during Azole Therapy: a Case Study and Review of the LiteratureAntimicrobial Agents and Chemotherapy, 2012
- Azole Resistance in Aspergillus fumigatus Isolates from the ARTEMIS Global Surveillance Study Is Primarily Due to the TR/L98H Mutation in the cyp51A GeneAntimicrobial Agents and Chemotherapy, 2011
- High-frequency Triazole Resistance Found In Nonculturable Aspergillus fumigatus from Lungs of Patients with Chronic Fungal DiseaseClinical Infectious Diseases, 2011
- Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance NetworkJournal of Clinical Microbiology, 2009
- Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure1Emerging Infectious Diseases, 2009
- Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2008
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A AlterationsAntimicrobial Agents and Chemotherapy, 2007